Cambridge Nutritional Sciences (LSE:CNSL) Long-Term Debt: £0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cambridge Nutritional Sciences Long-Term Debt?

Cambridge Nutritional Sciences LSE:CNSL Long-Term Debt is £0.00 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Cambridge Nutritional Sciences's Long-Term Debt for the quarter that ended in Mar. 2026 was £0.00 Mil.

Cambridge Nutritional Sciences  (LSE:CNSL) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Cambridge Nutritional Sciences Long-Term Debt Related Terms

Cambridge Nutritional Sciences Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Cambridge Nutritional Sciences's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cambridge Nutritional Sciences Long-Term Debt Chart

Cambridge Nutritional Sciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cambridge Nutritional Sciences Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of £0.00 Mil mean?
Cambridge Nutritional Sciences (LSE:CNSL) has a Long-Term Debt of £0.00 Mil as of Mar. 2026.
Is Cambridge Nutritional Sciences' Long-Term Debt too high?
Cambridge Nutritional Sciences' current Long-Term Debt is £0.00 Mil.
How does Cambridge Nutritional Sciences' Long-Term Debt compare to ISRG and BDX?
Cambridge Nutritional Sciences' Long-Term Debt of £0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Cambridge Nutritional Sciences's current Long-Term Debt is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cambridge Nutritional Sciences stock overvalued right now?
Based on GuruFocus' analysis, Cambridge Nutritional Sciences (LSE:CNSL) is currently considered Modestly Undervalued. The stock's GF Value™ is £0.02, compared to a current price of £0.01 — trading 27.5% below its estimated fair value. The current Long-Term Debt is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Cambridge Nutritional Sciences (LSE:CNSL), the current Long-Term Debt is £0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cambridge Nutritional Sciences Business Description

Other Exchanges RVKA:Germany
Address One Fleet Place, London, GBR, EC4M 7WS
Omega Diagnostics Group PLC is a UK-based medical diagnostics company. It develops, manufactures, and distributes in vitro diagnostic tests, historically organized around food sensitivity testing, allergy and autoimmune testing, and infectious disease diagnostics. Its food sensitivity products, marketed under brands such as Food Detective and FoodPrint, are used by healthcare professionals and laboratories to identify immune reactions to foods. The company also supplies allergy testing kits and, during the COVID-19 pandemic, produced lateral flow antigen tests. Omega serves customers including clinical laboratories, hospitals, research institutions, and healthcare providers, selling primarily in the United Kingdom, Europe, and through distributors in other international markets. Revenue is generated through the sale of diagnostic test kits and related consumables, with additional income from contract manufacturing and licensing arrangements. The company has undergone significant restructuring, including the sale of its infectious disease business and a rebranding of its food sensitivity operations.